- BiolineRx (NASDAQ:BLRX) FY16 results: Revenues: $0; R&D Expense: $11.2M (-2.6%); SG&A: $5.3M (+12.8%); Operating Loss: ($16.5M) (-1.9%); Net Loss: ($15.8M) (-9.7%); Loss Per Share: ($0.28) (unch); Quick Assets: $35.6M (-25.4%).
- No guidance given.
- Shares are down 0.9% premarket.
BiolineRx reports FY16 results
Recommended For You
About BLRX Stock
Related Stocks
Symbol | Last Price | % Chg |
---|---|---|
BLRX | - | - |
BioLineRx Ltd. |